Thyroid glands affected by Graves' disease (GD) show striking lymphocytic infiltration, mainly by CD45RO ϩ T cells. The mechanisms by which the various lymphocytic subsets are recruited and maintained in the thyroid are unknown. RANTES (regulated on activation, normal T cells expressed and secreted) in interaction with its receptors (CCR1, CCR3, CCR4 and CCR5) may be one of the favorite chemokines involved in the cell trafficking and maintenance.
examined various thyroid-derived cells. Lymphocytes showed a markedly higher basal RANTES mRNA and protein level (mean Ϯ SEM; pg/mL, n ϭ 3; 140 Ϯ 30) than thyrocytes (12 Ϯ 5) and fibroblasts (9 Ϯ 2). Lymphocyte stimulation with PMA enhanced RANTES secretion significantly (4490 Ϯ 200). Fibroblasts responded to stimulation with interleukin 1 (530 Ϯ 220) and tumor necrosis factor ␣ (2780 Ϯ 1790), whereas thyrocytes did not. However, some thyroid carcinoma cell lines showed very high basal and stimulated RANTES expression.
Lymphocytes expressed the mRNA of all chemokine receptors that bind RANTES. The number of CCR3 ϩ and CCR5 ϩ T cells was significantly higher in thyroid-derived leukocytes than in those in the peripheral blood stream.
We conclude that RANTES expression, mainly by lymphocytes, is perhaps involved in the maintenance of lymphocytic infiltration and, therefore, in the autoimmune responses in GD. (J Clin Endocrinol Metab 85: 4758 -4764, 2000) O NE OF THE hallmarks of thyroids affected by Graves' disease (GD) is lymphocytic infiltration, principally by memory T (CD45R0 ϩ ) and B cells (1) (2) (3) . The trafficking and maintenance of immune cells is complex, involving the interactions of an entire superfamily of chemoattractant cytokines (chemokines) and their receptors (4, 5) . The chemokine system provides the necessary flexibility for determining the migratory patterns of various types of leukocytes precisely (6) . Chemokines are 8 -10 kDa proteins that have been subdivided into four families on the basis of the relative position of their cysteine residues. Only the largest families (CC and CXC) have been extensively characterized. In contrast to CXC-chemokines, CC-chemokines do not act on neutrophils but attract lymphocytes, monocytes, and other leukocyte subsets with variable selectivity. So far as the thyroid is concerned, little information is available on the recruitment and maintenance of the various lymphocytic subsets by chemokines under normal and pathological conditions. The CC-chemokine RANTES (regulated on activation, normal T cells expressed and secreted) is one of those most likely to attract and maintain specific leukocyte subsets in the thyroid gland in GD because it is a chemoattractant for memory T cells and monocytes (7) . Ashhab et al. (8) recently reported their demonstration of the marked expression of various types of chemokine messenger RNA (mRNA) in thyroid tissue, including RANTES. However, they did not find any significant difference in the expression of the latter in nonautoimmune multinodular goiter and GD. Analysis of the serum of their GD patients revealed no or only very low levels of autoantibodies against thyroid peroxidase (TPO), which is actually uncommon for these patients (9 -11) . No data are available on the cellular sources of RANTES, on RANTES regulation, or on the expression of those chemokine receptors able to bind RANTES in the thyroid gland.
The aim of our study was to investigate the expression of RANTES mRNA in the thyroid tissue of patients with GD who had low or high serum levels of antibodies against TPO and the TSH receptor [TSH-binding inhibiting immunoglobulin (TBII)]. Thyroid tissue of patients with thyroid autonomy (TA) , carefully separated in autonomous and quiescent tissue, was included in our study. The RANTES mRNA levels were related to the levels of thyroid autoantibodies and/or thyroidal T-cell infiltration. Because RANTES may be produced by a variety of cell types and induced by a variety of stimuli (12, 13) , we further examined the expression and regulation of RANTES mRNA and protein in a number of thyroid-derived cells such as lymphocytes, thyrocytes, and fibroblasts. Thyroid carcinoma cell lines were used to confirm RANTES expression by thyrocytes. Expression of the CC-chemokine receptors CCR1, CCR3, CCR4, and CCR5 binding RANTES (5) was also investigated.
Materials and Methods Patients
GD (2 males and 14 females; mean age Ϯ sem, 40.8 Ϯ 2.8 yr) and TA (n ϭ 7, all female; mean age Ϯ sem, 57.4 Ϯ 2.8 yr) were diagnosed on the basis of its clinical, biochemical, and immunological features, as well as from scintiscans. Fourteen of 16 GD patients treated with methimazole or propylthiouracil for more than 8 months were clinically euthyroid and had normal free T 4 and T 3 levels at the time of operation. Two of the patients were undergoing surgery within 2 months after diagnosis without antithyroid drug treatment. From all patients with unifocal TA thyroid scans using Tc-99m, pertechnatate showed a single hot nodule with a low uptake in the rest of the thyroid.
Antibodies against the TSH receptor (TBII) and TPO were measured in serum obtained during the 2 weeks before operation with commercial RIA kits (Henning, Berlin, Germany). GD patients could be divided further into two groups of eight patients each: patients with high (Ͼ4000 U/mL) and patients with low (Ͻ200 U/mL) or zero serum anti-TPO levels. The correlation between the RANTES mRNA levels and the serum anti-TPO, TBII levels, or T lymphocytic infiltration (see below) was calculated by Spearman's method.
Estimation of T-cell infiltration in thyroid sections
Thyroid samples from patients with GD were obtained at operation. The fat and connective tissue were removed immediately. In TA, the tissue was carefully separated in adenomous and quiescent tissue. In all cases, the presence of a capsule was checked. The samples were frozen and stored in liquid nitrogen until required. Cryostat sections (4 m) were fixed in acetone (7 min), blocked, and stained with an anti-CD3 monoclonal antibody by the alkaline phosphatase antialkaline phosphatase method (all antibodies from Dianova, Hamburg, Germany), as described by Heuer et al. (14) . After counterstaining with hematoxylin, the number of T cells was graded semiquantitatively (14, 15) : 0 ϭ no; 1 ϭ few (Ͻ5%); 2 ϭ moderate number of (5-25%); and 3 ϭ many (Ͼ25%) positive cells. T-cell infiltration strongly correlates with the overall lymphocytic and leukocytic infiltration (14) .
Preparation of thyroid-derived cells and cell lines
Thyroid-derived cells were prepared from five thyroids of patients with GD. Thyrocytes and lymphocytes were enriched after gradual enzymatic tissue digestion and cultured over a period of 16 h, as described (3). Thyrocytes were obtained from the adherent fraction by incubating the cell monolayer with PBS in the absence of Ca 2ϩ /Mg 2ϩ for 45 min (16) . Residual fibroblasts within the thyrocyte fraction were eliminated by incubating with the fibroblast-specific monoclonal antibody FibAS01 and goat-antimouse IgG-Dynabeads M450 (DynAl GmbH, Hamburg, Germany) (16) . Thyroid-derived lymphocytes were enriched from the nonadherent fraction by Ficoll density gradient centrifugation (17) . By culturing small pieces of thyroid tissue in DMEM (Life Technologies, Grand Island, NY) with 10% FCS, outgrowing fibroblasts were obtained, harvested, and used in the fifth to seventh passage. The purity of the isolated thyroid-derived cells was determined by using the indirect immunofluorescence technique on a FACS-Scan (Becton Dickinson and Co., Mountain View, CA) (3, 16) . The human anaplastic thyroid carcinoma lines C 643, SW 1736, and HTh 74 were kindly provided by Dr. N.-E. Heldin (University of Uppsala, Uppsala, Sweden). The original dedifferentiated papillary carcinoma line 8505 C and the follicular carcinoma line FTC-133 were purchased from the German Collection of Microorganisms and Animal Cell Cultures. All cell lines were cultured in DMEM/10% FCS.
In vitro cultures
Cells (1 ϫ 10 5 )/well were cultured on 24-well plates for 24 h. The medium was aspirated and replaced with 500 L OPTI-MEM (Life Technologies) without FCS to eliminate possible stimulation by the latter. The medium contained the desired concentration of human interleukin (IL)-1␣ (10 U/mL; Sigma, Deisenhofen, Germany), tumor necrosis factor ␣ (TNF-␣) (5 ng/mL; Sigma), lipopolysaccharide Escherichia coli 055:B5 (LPS; 100 ng/mL; Sigma), or 10 ng/mL PMA (Sigma). For each stimulator, triplicate cultures were analyzed. The maximum or plateau of RANTES mRNA or protein expression was determined with HTh 74 cells taken as a standard. The RANTES mRNA level reached a plateau after about 12 h and was then analyzed. The highest RANTES protein levels were measured after 48 h. After this, the protein level decreased, probably because of proteolytic degradation (data not shown). In lymphocytes, the RANTES mRNA and protein levels were examined after 6 and 12 h, because without stimulation the cells died during this time and it was, therefore, impossible to measure the basal quantity any later. The supernatants were removed, frozen, and assayed for RANTES by enzyme-linked immunosorbent assay (ELISA; Amersham Pharmacia Biotech, Freiburg, Germany). Lysis buffer (0.2 mL) from the QIAGEN total RNA isolation kit (QIAGEN GmbH, Hilden, Germany) was added to each well; the contents of three wells were then pooled for each cell type and frozen in liquid nitrogen for further mRNA analysis. The protein levels of cultures obtained from separate experiments were presented as mean Ϯ sem. The Mann-Whitney test was used to determine the statistically significant difference between basal and stimulated cells.
RNA isolation and complementary DNA (cDNA) synthesis
Total cellular RNA was isolated from thyroid tissue and cell cultures with the QIAGEN total RNA isolation kit (QIAGEN), in accordance with the manufacturer's instructions. Genomic DNA was digested with 0.02 U DNase/g RNA (Roche Molecular Biochemicals, Mannheim, Germany) at 25 C for 10 min. Five micrograms of total RNA was taken to synthesize cDNA, using a first-strand cDNA synthesis kit from Amersham Pharmacia Biotech (Freiburg, Germany) in a reaction volume of 15 L.
Semiquantitative competitive RT-PCR
Gylceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was quantified in accordance with the published method (18) . To quantify human RANTES cDNA, a rapid one-step method was introduced to synthesize an internal homologous competitor (19, 20) . Amplification of thyroid tissue cDNA with the RANTES sense and RANTES hybrid primers (see Table 2 ) resulted in a 375-bp RANTES competitor. The competitor was purified from excess primers and dNTPs, using the QIAquick Gel Extraction Kit (QIAGEN GmbH) and quantified. The competitors were stabilized at defined concentrations in the PCR tubes by the method of Kö hler et al. (21) .
Variations between different cDNA preparations were corrected. All the samples were first adjusted to contain equal concentrations of GAPDH cDNA in a semiquantitative RT-PCR (20) . We then estimated RANTES cDNA in these adjusted samples. cDNA samples were titrated into RT-PCR amplification solutions containing known copies of the competitor. Both the sample cDNA and the competitor were coamplified, using the RANTES sense and RANTES antisense primers. Two products were generated. One was derived from the cDNA (477 bp) and the other, 102 bp smaller in size, from the RANTES competitor. The corresponding fragments for GAPDH PCR were 567 bp (sample cDNA) and 477 bp (competitor) in length. Based on the difference in length, the sample cDNA and competitor PCR products were resolved by gel electrophoresis. The sample cDNA and competitor were quantified by measuring the intensity of ethidium fluorescence with a cooled CCD 8-bit image sensor and the data analyzed by Phoretix 1 D plus software (Phoretix International, Newcastle-upon-Tyne, UK). The target copies equation was used to determine the ratio of sample cDNA copies/PCR to the number of competitor copies added, multiplied by the quotient of the cDNA signal and divided by the competitor signal. Each 25 L amplification reaction contained 2.5 L 10ϫ concentrated PCR buffer (15 mm MgCl 2 ), 0.3 U Taq DNA polymerase (Roche Molecular Biochemicals, Mannheim, Germany), 100 m dNTPs, 0.1 m of each primer, 1 L sample cDNA, and the stabilized competitor in adjusted dilutions.
Intracellular RANTES staining
The method for intracellular staining was adapted from that of Sander et al. (22) . Peripheral blood (2 ϫ 10 6 ) or thyroid-derived lymphocytes from the same patient (n ϭ 4) were incubated with 0.1 g/mL lipopolysaccharide and 2 mol/L monensin (Sigma) for 24 h. The cells were washed twice in PBS/1%FCS, then fixed with 0.5 mL ice-cold 4% parformaldehyde/PBS for 10 min. After washing, the cells were resuspended in PBS containing 0.3% saponin (Sigma). The cells were incubated for simultaneous surface and intracellular staining with CD8-FITC (PharMingen Deutschland GmbH, Hamburg, Germany), CD3-CyChrome, and RANTES-PE (R&D Systems GmbH, Wiesbaden, Germany) for 30 min at 4 C. After washing, the cells were analyzed by flow cytometry.
Chemokine receptor analysis
CCR1, CCR3, CCR4, and CCR5 mRNA expression was analyzed for all thyroid-derived cell types and thyroid carcinoma cell lines by RT-PCR (primers see Table 1 ). mRNA from peripheral blood mononuclear cells that had been isolated by Ficoll density gradient centrifugation served as a positive control. To determine chemokine receptor protein expression, 2 ϫ 10 5 cells were stained with directly fluorochromelabeled monoclonal antibodies at the desired concentration for 20 min at 4 C (CCR5-phycoerythrin, CD3-CyChrome, PharMingen; CCR3-phycoerythrin, R&D Systems) or by means of an indirect immunofluorescence technique (CCR1, R&D Systems GmbH; CCR4, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The cells were analyzed by flow cytometry.
Results

RANTES mRNA levels in thyroid tissues of patients with GD and TA
All the thyroid tissues investigated were RANTES mRNA positive (Fig. 1) . In GD patients, the RANTES mRNA level correlated with the TPO antibodies (r ϭ 0.76; P Ͻ 0.001) and T-cell infiltration (r ϭ 0.68; P Ͻ 0.005). GD patients with high TPO antibodies showed a significantly higher RANTES mRNA level (10 Ϫ21 mol RANTES cDNA/PCR; mean Ϯ sem, 349 Ϯ 72) than patients with no or low anti-TPO antibodies (73 Ϯ 17; P Ͻ 0.005). Among GD patients with high TPO antibodies, the two patients with the lowest RANTES mRNA levels showed the least amount of TPO antibodies and of T-cell infiltration. The RANTES mRNA level did not correlate with the TBII antibodies (r ϭ 0.36). The RANTES mRNA levels of the two untreated GD patients, one with zero and one with high anti-TPO levels were 67.5 and 404 ϫ 10 Ϫ21 mol RANTES cDNA/PCR, respectively.
In TA, RANTES mRNA levels did not correlate with T-cell infiltration. There was no difference in RANTES mRNA levels between 1) the autonomous nodules (108 Ϯ 30) and the quiescent sourrounding tissue (130 Ϯ 29) in TA patients and 2) the autonomous or quiescent tissues of TA patients and the tissues of patients with GD showing low T-cell infiltration. RANTES mRNA levels of both tissues of TA patients and tissues of GD patients with high anti-TPO levels and high T-cell infiltration differed significantly (P Ͻ 0.05).
RANTES mRNA and protein expression in thyroid-derived cells
To define the cellular source of RANTES mRNA, we investigated isolated thyroid-derived cell populations. Lym- phocytes expressed a more than 300 higher basal RANTES mRNA level than fibroblasts, and secreted RANTES (mean Ϯ sem; n ϭ 3; 140 Ϯ 30 pg/ml) under basal conditions (Fig. 2) . PMA (4490 Ϯ 200 pg/mL) and LPS (480 Ϯ 140 pg/mL) increased RANTES secretion significantly, whereas IL-1 or TNF-␣ did not. This result was confirmed by flow cytometry (data not shown). Unstimulated fibroblasts expressed RAN-TES mRNA near the detection limit and secreted only small amounts of protein (Fig. 3) . Stimulation with both IL-1 and TNF-␣ induced RANTES secretion up to 5 ng/mL after 48 h. Thyrocytes produced small amounts of RANTES under basal conditions (Fig. 4) , and showed a slight, insignificant increase after stimulation with IL-1 or TNF-␣ (n ϭ 5; basal, 12 Ϯ 4 pg/ml; IL-1, 18 Ϯ 7 pg/mL; TNF-␣, 22 Ϯ 10 pg/mL). The low basal levels could have been attributed to a small number of contaminating lymphocytes, but this possibility had been excluded by flow cytometry. Only treatment with PMA enhanced RANTES secretion up to 30-fold after 48 h (Fig. 2C ), but this increase may have been related to the cytotoxic effects of PMA on thyrocytes, because the number of dead cells among the thyrocytes increased conspicuously during PMA treatment (data not shown).
RANTES mRNA and protein expression in thyroid tumor cell lines
To confirm that thyrocytes may actually express RANTES, we examined five thyroid carcinoma cell lines. All of them expressed RANTES mRNA and protein under basal conditions, although the levels varied considerably. Cell lines with high levels of basal RANTES mRNA showed higher basal RANTES protein expression than cell lines with low basal levels. Unstimulated FTC-133, 8505 C, and C643 cells secreted more than 500 pg/mL RANTES. The basal RANTES mRNA (1.2 ϫ 10 Ϫ19 RANTES cDNA/PCR) and protein expression (1400 Ϯ 24 pg/mL) by C 643 cells may be of physiological relevance.
Although FTC-133, 8505C, and SW 1736 cells express IL-1 and TNF-␣ receptors (20) and respond to cytokine or PMA stimulation with an increase in granulocyte macrophage colony-stimulating factor or matrix-metalloproteinase mRNA and protein expression (18, 20) , there is no, or only a slight, up-regulation of RANTES after stimulation (data not shown). On the other hand, basal RANTES negative HTh 74 cells showed a strong induction of RANTES both in the mRNA and protein levels after PMA (1100 Ϯ 46 pg/mL) and TNF-␣ (1000 Ϯ 44 pg/mL) but not IL-1 treatment.
Intracellular staining of RANTES
Compared with peripheral blood lymphocytes, a 2-to 3-fold quantity of thyroid-derived CD3 ϩ lymphocytes expressed RANTES in the same patient (n ϭ 4; mean Ϯ sem; periphery: 12.9 Ϯ 2.3%; thyroid: 35.0 Ϯ 8.0%; P ϭ 0.05). In the periphery (89.1 Ϯ 3.0%) as well as in the thyroid (92.8 Ϯ 1.0%), most of the RANTES ϩ cells were CD3 ϩ lymphocytes. Among the RANTES ϩ CD3 ϩ lymphocytes, nearly half of the cells expressed the CD8 antigen (periphery, 41.6 Ϯ 8.9%; thyroid, 54.1 Ϯ 3.6%). Figure 5 shows the typical staining pattern of one patient with GD. Thyrocytes as well a thyroidderived fibroblasts did not show intracellular RANTES staining (data not shown).
RANTES chemokine receptor mRNA and protein expression
Mononuclear cells circulating in the peripheral blood and separated by density gradient centrifugation served as a positive control for the expression of chemokine receptors.
Thyroid-derived lymphocytes and thyrocytes expressed all the chemokine receptor mRNAs investigated. The mRNA signals obtained from leukocytes were usually much stronger than those from thyrocytes. The cell lines, as well as the fibroblasts, were either negative or showed only very faint signals for CCR1, CCR5, and CCR4 mRNA. All cell types and cell lines were positive for CCR3 mRNA (Fig. 5) .
These results correlate well with the data obtained by flow cytometry. A small number of CCR3 ϩ cells (between 2% and 11%) were detected within each cell type analyzed. The CCR3 expression did not correlate with the degree of activation of the cells. The few CCR3 ϩ and CCR5 ϩ cells among the thyrocytes could not be characterized as remaining leukocytes (data not shown). RANTES chemokine receptor expression was further examined by double labeling with an anti-CD3 monoclonal antibody on lymphocytes in the peripheral blood and those derived from the thyroid of the same patient (n ϭ 3, Fig. 7 ). The number of CCR3 ϩ and CCR5 ϩ T cells in the thyroid was significantly higher (CCR3 ϩ within CD3 
Discussion
Our data on patients with GD clearly demonstrate that thyroids with high lymphocytic infiltration show signifi- cantly higher RANTES mRNA levels than those with low infiltration. This finding reflects the maintenance of an immune response rather than its initiation, because most of the thyroid samples were obtained more than eight months after diagnosis. Two thyroid samples obtained immediately after diagnosis of GD showed RANTES mRNA levels in the same range as samples from antithyroid drug-treated patients. The RANTES mRNA level and the density of lymphocytic infiltration correlate with the levels of TPO, but not with those of TBII antibodies. This is in accordance with the literature. The intensity of the intrathyroidal immune process is better reflected by the levels of TPO than of the TBII antibodies (23) . Our routine TBII assay did not allow us to distinguish between thyroid stimulating and blocking antibodies, which may correlate better with lymphocytic infiltration. Unlike us, Ashhab et al. (8) investigated GD patients with few or no anti-TPO antibodies. Because such patients show only a small amount of lymphocytic infiltration, these authors probably failed to recognize a significant difference between the RANTES mRNA levels in the tissues of patients with nonautoimmune multinodular goiter and those with GD. Our results from autonomous nodules and the quiescent surrounding tissue suggest that RANTES levels reflect immunological as opposed to functional differences in the thyroid. However, RANTES is not the only chemokine responsible for attracting lymphocytes into the thyroid, which is overexpressed in GD (8) . There is a complex network involving the selective and coordinated production of individual chemokines and the expression of chemokine receptors capable of attracting selective leukocyte subpopulations into the thyroid. The maintenance of the lymphocytic infiltrate in GD tissue is not a static condition. Increasing variability of T-cell clones, significantly more activated T-cells (15, 24, 25) and interferon-␥ or TNF-␣ producing lymphocytes (16, 25) in the thyroid than in the peripheral blood of the same patient during the course of GD, even after long treatment, reflects long-standing active immunological processes in the thyroid. Activated T cells are very potential for producing RANTES (12, 13) . In our study, thyroid-derived lymphocytes showed the highest basal expression of RANTES mRNA. Intracellular staining of RANTES clearly demonstrates that thyroidderived lymphocytes possessed a higher capacity to produce RANTES compared with peripheral blood lymphocytes of the same patient. It is not clear whether the high RANTES level is the reason for dense lymphocytic infiltration or whether the high RANTES level is caused by present lymphocytes that have received other specific chemokine signals inducing their migration into the thyroid. An autocrine feedback between recruited lymphocytes and RANTES production is also conceivable.
As the data have shown, RANTES expression is not limited to activated T cells (26) . It is interesting that thyrocytes produce small amounts of RANTES under basal conditions, which suggests that one possible role of thyrocytes is to participate in the migration of T lymphocytes and monocytes into the thyroid from the blood stream. Although it is well known that in vitro thyrocytes produce a greater variety of cytokines than any other endocrine cells (27) , only two chemokines, IL-8 and monocyte chemoattractant protein-1, have been investigated (28, 29) . Both have been found in untreated thyrocytes as has been shown here in the case of RANTES. Intracellular staining of RANTES could not been demonstrated, probably due to the limited sensitivity of the method compared with the ELISA system.
To confirm our observations on the expression of RANTES in thyrocytes, we examined five thyroid carcinoma cell lines. Four expressed higher basal RANTES levels than thyrocytes. The basal or inducible RANTES expression of all investigated tumor cell lines indicate that thyrocytes can acquire this capability after malignant transformation. As has already been demonstrated, cell lines from the same tissue often produce higher RANTES levels than the normal unstimulated cells (30) . Physiologically relevant levels of intrinsic RANTES production have been shown in the tumor cell lines from two breast carcinomas and four of eight melanomas (30, 31) . It is of particular interest that RANTES production by tumor cells seems to be a mediator for the recruitment of tumor-infiltrating lymphocytes and macrophages as inhibitors of tumor growth (31, 32) . RANTES may augment the host response to tumors. On the other hand, more malignant cells expressed higher RANTES levels than did the less malignant cells (30, 33) . Transplantation experiments in nude mice suggest that effects of RANTES may also benefit tumor progression. This is why data on RANTES expression by thyroid cell lines can only be assessed in thyroid tumors. Finally, fibroblasts may be potential RANTES producers (34) . In our study, IL-1 and TNF-␣ induced strong RANTES secretion by basal negative thyroid-derived fibroblasts.
To determine RANTES binding to thyroid-derived cells, we identified their expression of the chemokine receptors CCR1, CCR3, CCR4, and CCR5. All of these receptors can bind more chemokines than RANTES alone (6) . Although the complex interactions between the different ligands and receptors in vivo cannot be detected by our current assays, the detection of RANTES binding receptors on thyroid-derived cells provides a first insight into the possible regulatory mechanisms. Thyroid-derived lymphocytes were positive for all the chemokine receptor mRNAs analyzed. CCR3 and CCR5 are both expressed to a greater extent by thyroidderived T cells than by T cells in the peripheral blood of the same patient. The very small number of CCR3 ϩ and CCR5 ϩ T cells in the peripheral blood confirms the data reported by other groups (35) . Because CCR3 expression identifies T cells capable of producing IL-4 (the key feature of Th2 cells), and CCR5 expression reflects the T-cell activation state, the more pronounced expression of CCR3 and CCR5 on thyroidderived T cells may reflect the autoimmune process within the thyroid. Furthermore, flow cytometry analysis showed that a few cells among the thyrocytes also expressed CCR3 and CCR5, which could not be observed to contain lymphocytes. Chemokine receptor mRNAs have recently been identified on intestinal epithelial cells (36) . These data indicate that epithelial cells may be able to serve as targets for chemokine signaling. In summary, we found a clear correlation between the intensity of lymphocytic infiltration and the RANTES mRNA levels in the thyroid tissue of patients with GD. Lymphocytes themselves are the main source of RANTES in the thyroid. RANTES may use CCR3 and CCR5 to bring about the autocrine or paracrine stimulation of lymphocytes. The low RANTES levels in thyrocytes may be a feature of normal thyroid physiology. On the other hand, the high level of basal RANTES expression in some of the thyroid carcinoma lines analyzed here suggests that RANTES plays a part in thyroid tumors.
